BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34110110)

  • 1. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia.
    Rinonce HT; Sastri DJ; Trisnawati F; Kameswari B; Ferronika P; Irianiwati
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1454. PubMed ID: 34110110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients.
    Rinonce HT; Aji RPM; Hayati N; Pudjohartono MF; Kameswari B; Irianiwati
    BMC Proc; 2019; 13(Suppl 11):15. PubMed ID: 31890008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
    Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
    Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
    Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
    J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRAS mutations in primary and metastatic melanomas of Japanese patients.
    Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
    Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
    Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
    J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of NRAS isoforms in Chinese melanoma patients.
    Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
    Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of distinct molecular profile of Primary Dermal Melanoma.
    Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
    Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.